Stay updated with breaking news from Beth Hecht. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos' established,
m ET ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. Transaction Details Upon the e...